# RAW SEQUENCE LISTING

**The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) no errors detected.**

Application Serial Number: 10/533,826A
Source: FWO
Date Processed by STIC: 8/23/06

# *ENTERED*

# CRF Errors Edited by the STIC Systems Branch

Serial Number: 10/533,826A

CRF Edit Date: 8/23/06
Edited by: BC

___ Realigned nucleic acid/amino acid numbers/text in cases where the sequence text "wrapped" to the next line

___ Corrected the SEQ ID NO. Sequence numbers edited were:

_____

___ Inserted or corrected a nucleic number at the end of a nucleic line. SEQ ID NO's edited:

_____

/ / Deleted: ___ invalid beginning/end-of-file text ; ___ page numbers

___ Inserted mandatory headings/numeric identifiers, specifically:

_____

___ Moved responses to same line as heading/numeric identifier, specifically:

_____

___ Other:

_____

_____

_____

Revised 09/09/2003

IFWO

RAW SEQUENCE LISTING DATE: 08/23/2006
PATENT APPLICATION: US/10/533,826A TIME: 18:29:29

Input Set : A:\PTO.AMC.txt
Output Set: N:\CRF4\08232006\J533826A.raw

<110> APPLICANT: Marx, Gerard
Gorodetsky, Raphael
<120> TITLE OF INVENTION: Liposomal Compositions Comprising Haptotactic Peptides
<130> FILE REFERENCE: 2488.014
<140> CURRENT APPLICATION NUMBER: US 10/533,826A
<141> CURRENT FILING DATE: 2005-05-03
<150> PRIOR APPLICATION NUMBER: PCT/IL03/000911
<151> PRIOR FILING DATE: 2003-11-03
<150> PRIOR APPLICATION NUMBER: IL 152609
<151> PRIOR FILING DATE: 2002-11-03
<160> NUMBER OF SEQ ID NOS: 14
<170> SOFTWARE: PatentIn version 3.1
<210> SEQ ID NO: 1
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Equivalent to the c-terminus of fibrinogen beta-chain
<400> SEQUENCE: 1
Lys Gly Ser Trp Tyr Ser Met Arg Lys Met Ser Met Lys Ile Arg Pro
1 5 10 15
Phe Phe Pro Gln Gln
20
<210> SEQ ID NO: 2
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Equivalent to the c-terminus of fibrinogen alphaE chain
<400> SEQUENCE: 2
Arg Gly Ala Asp Tyr Ser Leu Arg Ala Val Arg Met Lys Ile Arg Pro
1 5 10 15
Leu Thr Val Thr Gln
20
<210> SEQ ID NO: 3
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Equivalent to the c-terminus of fibrinogen pre-gama chain
<400> SEQUENCE: 3
Lys Thr Arg Trp Tyr Ser Met Lys Lys Thr Thr Met Lys Ile Ile Pro
1 5 10 15

RAW SEQUENCE LISTING DATE: 08/23/2006
PATENT APPLICATION: US/10/533,826A TIME: 18:29:29

Input Set : A:\PTO.AMC.txt
Output Set: N:\CRF4\08232006\J533826A.raw

```
     73 Phe Asn Arg Leu
     74             20
     77 <210> SEQ ID NO: 4
     78 <211> LENGTH: 19
     79 <212> TYPE: PRT
     80 <213> ORGANISM: Artificial sequence
     82 <220> FEATURE:
     83 <223> OTHER INFORMATION: Equivalent to the c-terminus of angiopoietin-1
     85 <400> SEQUENCE: 4
     87 Lys Gly Pro Ser Tyr Ser Leu Arg Ser Thr Thr Met Met Ile Arg Pro
     88 1               5                  10                  15
     91 Leu Asp Phe
     95 <210> SEQ ID NO: 5
     96 <211> LENGTH: 19
     97 <212> TYPE: PRT
     98 <213> ORGANISM: Artificial sequence
    100 <220> FEATURE:
    101 <223> OTHER INFORMATION: Equivalent to the c-terminus of angiopoietin-2
    103 <400> SEQUENCE: 5
    105 Lys Gly Ser Gly Tyr Ser Leu Lys Ala Thr Thr Met Met Ile Arg Pro
    106 1               5                  10                  15
    109 Ala Asp Phe
    113 <210> SEQ ID NO: 6
    114 <211> LENGTH: 19
    115 <212> TYPE: PRT
    116 <213> ORGANISM: Artificial sequence
    118 <220> FEATURE:
    119 <223> OTHER INFORMATION: Equivalent to the c-terminus of Tenascin X
    121 <400> SEQUENCE: 6
    123 Lys Gly Phe Glu Phe Ser Val Pro Phe Thr Glu Met Lys Leu Arg Pro
    124 1               5                  10                  15
    127 Asn Phe Arg
    131 <210> SEQ ID NO: 7
    132 <211> LENGTH: 17
    133 <212> TYPE: PRT
    134 <213> ORGANISM: Artificial sequence
    136 <220> FEATURE:
    137 <223> OTHER INFORMATION: Equivalent to c-terminus of Microfibril associated protein
    139 <400> SEQUENCE: 7
    141 Lys Gly Phe Tyr Tyr Ser Leu Lys Arg Pro Glu Met Lys Ile Arg Arg
    142 1               5                  10                  15
    145 Ala
    149 <210> SEQ ID NO: 8
    150 <211> LENGTH: 8
    151 <212> TYPE: PRT
    152 <213> ORGANISM: Artificial sequence
    154 <220> FEATURE:
    155 <223> OTHER INFORMATION: Peptide equivalent to the c-terminus of fibrinogen beta-
chain
    157 <400> SEQUENCE: 8
```

RAW SEQUENCE LISTING DATE: 08/23/2006
PATENT APPLICATION: US/10/533,826A TIME: 18:29:29

Input Set : A:\PTO.AMC.txt
Output Set: N:\CRF4\08232006\J533826A.raw

159 Lys Gly Ser Trp Tyr Ser Met Arg
160 1 5
163 <210> SEQ ID NO: 9
164 <211> LENGTH: 10
165 <212> TYPE: PRT
166 <213> ORGANISM: Artificial sequence
168 <220> FEATURE:
169 <223> OTHER INFORMATION: Peptide equivalent to the c-terminus of fibrinogen beta-chain
171 <400> SEQUENCE: 9
173 Lys Gly Ser Trp Tyr Ser Met Arg Lys Met
174 1 5 10
177 <210> SEQ ID NO: 10
178 <211> LENGTH: 10
179 <212> TYPE: PRT
180 <213> ORGANISM: Artificial sequence
182 <220> FEATURE:
183 <223> OTHER INFORMATION: Equivalent to the c-terminus of fibrinogen pre-gama chain
185 <400> SEQUENCE: 10
187 Lys Thr Arg Trp Tyr Ser Met Lys Lys Thr
188 1 5 10
191 <210> SEQ ID NO: 11
192 <211> LENGTH: 8
193 <212> TYPE: PRT
194 <213> ORGANISM: Artificial sequence
196 <220> FEATURE:
197 <223> OTHER INFORMATION: Equivalent to the c-terminus of angiopoietin-1
199 <400> SEQUENCE: 11
201 Lys Gly Pro Ser Tyr Ser Leu Arg
202 1 5
205 <210> SEQ ID NO: 12
206 <211> LENGTH: 10
207 <212> TYPE: PRT
208 <213> ORGANISM: Artificial sequence
210 <220> FEATURE:
211 <223> OTHER INFORMATION: Equivalent to c-terminus of Microfibril associated protein
213 <400> SEQUENCE: 12
215 Lys Gly Phe Tyr Tyr Ser Leu Lys Arg Pro
216 1 5 10
219 <210> SEQ ID NO: 13
220 <211> LENGTH: 16
221 <212> TYPE: PRT
222 <213> ORGANISM: Artificial sequence
224 <220> FEATURE:
225 <223> OTHER INFORMATION: Consensus sequence
227 <220> FEATURE:
228 <221> NAME/KEY: MISC_FEATURE
229 <222> LOCATION: (3)..(4)
230 <223> OTHER INFORMATION: Xaa is any non-charged amino acid or is absent
233 <220> FEATURE:

RAW SEQUENCE LISTING DATE: 08/23/2006
PATENT APPLICATION: US/10/533,826A TIME: 18:29:29

Input Set : A:\PTO.AMC.txt
Output Set: N:\CRF4\08232006\J533826A.raw

234 <221> NAME/KEY: MISC_FEATURE
235 <222> LOCATION: (10)..(11)
236 <223> OTHER INFORMATION: Xaa is any non-charged amino acid or is absent
239 <400> SEQUENCE: 13
W--> 241 Lys Gly Xaa Xaa Tyr Ser Met Arg Lys Xaa Xaa Met Lys Ile Arg Pro
242 1 5 10 15
245 <210> SEQ ID NO: 14
246 <211> LENGTH: 9
247 <212> TYPE: PRT
248 <213> ORGANISM: Artificial sequence
250 <220> FEATURE:
251 <223> OTHER INFORMATION: Consensus sequence
253 <220> FEATURE:
254 <221> NAME/KEY: MISC_FEATURE
255 <222> LOCATION: (3)..(4)
256 <223> OTHER INFORMATION: Xaa is any non-charged amino acid or is absent
259 <400> SEQUENCE: 14
W--> 261 Lys Gly Xaa Xaa Tyr Ser Met Arg Lys
262 1 5

RAW SEQUENCE LISTING ERROR SUMMARY DATE: 08/23/2006
PATENT APPLICATION: US/10/533,826A TIME: 18:29:30

Input Set : A:\PTO.AMC.txt
Output Set: N:\CRF4\08232006\J533826A.raw

Please Note:
Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:13; Xaa Pos. 3,4,10,11
Seq#:14; Xaa Pos. 3,4

VERIFICATION SUMMARY DATE: 08/23/2006
PATENT APPLICATION: US/10/533,826A TIME: 18:29:30

Input Set : A:\PTO.AMC.txt
Output Set: N:\CRF4\08232006\J533826A.raw

L:241 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13 after pos.:0
L:261 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14 after pos.:0

# Raw Sequence Listing before editing (for reference only)

IFWO

**RAW SEQUENCE LISTING** DATE: 08/18/2006
PATENT APPLICATION: **US/10/533,826A** TIME: 09:13:38

Input Set : **A:\2488014 sequence listing.txt**
Output Set: **N:\CRF4\08182006\J533826A.raw**

3 <110> APPLICANT: Marx, Gerard
4 Gorodetsky, Raphael
6 <120> TITLE OF INVENTION: Liposomal Compositions Comprising Haptotactic Peptides
8 <130> FILE REFERENCE: 2488.014
10 <140> CURRENT APPLICATION NUMBER: US 10/533,826A
11 <141> CURRENT FILING DATE: 2005-05-03
13 <150> PRIOR APPLICATION NUMBER: PCT/IL03/000911
14 <151> PRIOR FILING DATE: 2003-11-03
16 <150> PRIOR APPLICATION NUMBER: IL 152609
17 <151> PRIOR FILING DATE: 2002-11-03
19 <160> NUMBER OF SEQ ID NOS: 14
21 <170> SOFTWARE: PatentIn version 3.1

Does Not Comply
Corrected Diskette Needed

**ERRORED SEQUENCES**

245 <210> SEQ ID NO: 14
246 <211> LENGTH: 9
247 <212> TYPE: PRT
248 <213> ORGANISM: Artificial sequence
250 <220> FEATURE:
251 <223> OTHER INFORMATION: Consensus sequence
253 <220> FEATURE:
254 <221> NAME/KEY: MISC_FEATURE
255 <222> LOCATION: (3)..(4)
256 <223> OTHER INFORMATION: Xaa is any non-charged amino acid or is absent
259 <400> SEQUENCE: 14
**W--> 261 Lys Gly Xaa Xaa Tyr Ser Met Arg Lys**
262 1 5
**E--> 268** 6

**VERIFICATION SUMMARY** DATE: 08/18/2006
PATENT APPLICATION: **US/10/533,826A** TIME: 09:13:40

Input Set : **A:\2488014 sequence listing.txt**
Output Set: **N:\CRF4\08182006\J533826A.raw**

L:241 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13 after pos.:0
L:261 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14 after pos.:0
L:268 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:14